Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013

NCT04829318 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT04829318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04829318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
Lead sponsor
Janssen-Cilag Ltd.
Phase
Phase 4
Overall status
Completed
Start date
April 26, 2021
Completion date
July 22, 2024
Enrollment
183 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major